PMID- 22931381
OWN - NLM
STAT- MEDLINE
DCOM- 20130429
LR  - 20220318
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 80
IP  - 5
DP  - 2012 Nov
TI  - Detection of complement-fixing and non-fixing antibodies specific for endothelial 
      precursor cells and lymphocytes using flow cytometry.
PG  - 404-15
LID - 10.1111/j.1399-0039.2012.01954.x [doi]
AB  - Donor human leukocyte antigen (HLA)-specific antibodies (Abs) with the ability to 
      activate complement are associated with an increased risk of early Ab-mediated 
      rejection (AMR) of kidney allografts. In recent years, also non-HLA Abs-binding 
      endothelial cells have been shown to elicit early AMR. Donor-specific 
      anti-endothelial cell Abs escape detection in the pre-transplant evaluation if 
      only lymphocytes are used as target cells in crossmatch tests. We addressed 
      whether endothelial precursor cells (EPCs) could be used for detection of 
      complement-fixing as well as non-fixing Abs and if complement factor and 
      immunoglobulin G (IgG) deposition on co-purified T and B cells correlated to the 
      outcome of the T- and B-cell complement-dependent cytotoxicity assay. Deposition 
      of complement factors C3c and C3d, but not C1q nor C4d, were detected on EPCs and 
      lymphocytes upon incubation with HLA Ab-positive sera. There was a correlation 
      between the amount of C3c deposition and IgG binding on EPCs (R(2) = 0.71, P = 
      0.0012) and T cells (R(2) = 0.74, P = 0.0006) but not for B cells (R(2) = 0.34, P 
      = 0.059). The specificity and sensitivity for C3d deposition on endothelial 
      precursor cell crossmatch (EPCXM) T cells vs the T complement-dependent 
      cytotoxicity (CDC) assay were 69% and 72%, respectively. The EPCXM B-cell C3d 
      assay had considerably lower sensitivity (39%) than the B CDC assay. Altogether, 
      this novel assay based on the detection of complements factors on EPCs and 
      lymphocytes by flow cytometry may widen the diagnostic repertoire and thereby 
      improve the clinical management of patients undergoing kidney transplantation.
CI  - (c) 2012 John Wiley & Sons A/S.
FAU - AlMahri, A
AU  - AlMahri A
AD  - Division of Clinical Immunology and Transfusion Medicine, Karolinska Institute, 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Holgersson, J
AU  - Holgersson J
FAU - Alheim, M
AU  - Alheim M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120830
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Isoantibodies)
RN  - 0 (Peptide Fragments)
RN  - 80295-33-6 (Complement C1q)
RN  - 80295-44-9 (Complement C3c)
RN  - 80295-45-0 (Complement C3d)
RN  - 80295-50-7 (Complement C4b)
RN  - 80295-52-9 (complement C4d)
SB  - IM
MH  - Antibody Specificity
MH  - B-Lymphocytes/chemistry/*immunology
MH  - Cell Differentiation
MH  - Complement C1q/immunology
MH  - Complement C3c/immunology
MH  - Complement C3d/immunology
MH  - Complement C4b/immunology
MH  - Cytotoxicity Tests, Immunologic
MH  - Endothelial Cells/chemistry/*immunology
MH  - Flow Cytometry/*methods
MH  - Graft Rejection/diagnosis/*immunology
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Isoantibodies/*analysis/immunology
MH  - Kidney Transplantation/*immunology
MH  - Male
MH  - Peptide Fragments/immunology
MH  - Sensitivity and Specificity
MH  - T-Lymphocytes/chemistry/*immunology
MH  - Transplantation, Homologous
EDAT- 2012/08/31 06:00
MHDA- 2013/04/30 06:00
CRDT- 2012/08/31 06:00
PHST- 2012/02/08 00:00 [received]
PHST- 2012/06/21 00:00 [revised]
PHST- 2012/07/30 00:00 [accepted]
PHST- 2012/08/31 06:00 [entrez]
PHST- 2012/08/31 06:00 [pubmed]
PHST- 2013/04/30 06:00 [medline]
AID - 10.1111/j.1399-0039.2012.01954.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2012 Nov;80(5):404-15. doi: 10.1111/j.1399-0039.2012.01954.x. 
      Epub 2012 Aug 30.